LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Legal & Regulatory and Reimbursement/Aetna Attempts to Shut Down ConforMIS Lawsuit
Legal & Regulatory and Reimbursement

Aetna Attempts to Shut Down ConforMIS Lawsuit

August 11, 2020 2 min read Premium comments

Advertisement

Aetna Attempts to Shut Down ConforMIS Lawsuit
Courtesy of aetna, Pixabay, succo, and ConforMIS, Inc.
Secondary#conformis#aetna#employeeretirementincomesecurityact

Aetna, Inc. and Aetna Life Insurance Company (Aetna) have filed a motion to dismiss in an effort to end an ongoing battle with ConforMIS, Inc. and John Michael Schaub over the denial of claims for the use of customized total knee implants for knee replacement patients.

Earlier this year, ConforMIS and Schaub sued Aetna alleging Aetna violated its duties under the Employee Retirement Income Security Act (ERISA). ConforMIS’ additional claims against Aetna include product disparagement, tortious interference with a contractual relationship, and unfair trade practices. For OTW’s coverage of the lawsuit see, “Aetna’s Denial of ConforMIS Implants Results in Suit.”

In response, Aetna filed a motion to dismiss for failure to state a claim upon which relief can be granted. The motion was for all claims except for Schaub’s denial of benefits claim under ERISA.

In its motion to dismiss, Aetna stated, “The Complaint is ConforMIS’ novel, but improper, attempt to co-opt Mr. Schaub’s ERISA denial of benefits claim, and convert that claim into something it is not: a quasi-class action intended to force Aetna to cover the ConforMIS custom total knee replacement device nationwide under Aetna’s commercial health insurance benefit plans.”

Aetna seeks to dismiss all of ConforMIS’ claims. Aetna first argues that several of ConforMIS’ allegations against Aetna fail as a matter of law. Aetna also argues that ConforMIS’ tortious interference claim fails because the complaint alleges “no improper or intentional interference by Aetna in any actual contract or business relationship.”

Aetna makes several additional arguments in its motion to dismiss. Aetna argues that ConforMIS has no right to join in Schaub’s ERISA allegations because Schaub’s health plan contains an anti-assignment provision. Aetna asserts in the alternative that even if ConforMIS can sue under ERISA, ConforMIS should not be allowed to proceed on its breach of fiduciary duty claims because “Aetna cannot plausibly owe ConforMIS itself a fiduciary duty under ERISA.”

Aetna also requests that all of Schaub’s ERISA claims be dismissed, except for his wrongful denial of benefits claim. Aetna contends that Schaub lacks standing for his request and his claim for denial of full and fair review requires dismissal because the law “does not provide for a private right of action.”

OTW will continue to monitor the progress of the lawsuit. The parties have an initial scheduling conference set for August 31, 2020.

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy